[1]沈丹丹,王 鸿.溃疡性结肠炎活动期患者血清TRIM22 和KLF2 水平与病情及临床结局的关系[J].现代检验医学杂志,2024,39(04):143-149.[doi:10.3969/j.issn.1671-7414.2024.04.026]
　SHEN Dandan,WANG Hong.Relationship among Serum TRIM22 and KLF2 Levels, Disease Condition and Clinical Outcome of Patients with Active Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2024,39(04):143-149.[doi:10.3969/j.issn.1671-7414.2024.04.026]
点击复制

溃疡性结肠炎活动期患者血清TRIM22 和KLF2 水平与病情及临床结局的关系()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年04期
页码:
143-149
栏目:
论著
出版日期:
2024-07-15

文章信息/Info

Title:
Relationship among Serum TRIM22 and KLF2 Levels, Disease Condition and Clinical Outcome of Patients with Active Ulcerative Colitis
文章编号:
1671-7414（2024）04-143-07
作者:
沈丹丹; 王 鸿
（上海健康医学院附属崇明医院消化内科，上海 202150）
Author(s):
SHEN Dandan;  WANG Hong
(Department of Gastroenterology, Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai 202150, China)
关键词:
三结构域家族蛋白22; Kruppel 样转录因子2; 溃疡性结肠炎
分类号:
R574.62；R392.11
DOI:
10.3969/j.issn.1671-7414.2024.04.026
文献标志码:
A
摘要:
目的 探讨溃疡性结肠炎(ulcerative colitis，UC) 活动期患者血清三结构域家族蛋白22（tripartite motif protein22，TRIM22）、Kruppel 样转录因子2（Kruppel-like factor 2，KLF2）水平与病情及临床结局的关系。方法 选取上海健康医学院附属崇明医院2020 年1 月～ 2023 年1 月收治的97 例溃疡性结肠炎活动期患者为活动期组、56 例缓解期患者（缓解期组）和80 例健康体检者（对照组）为对照。活动期患者根据病情分为轻度组（n=46）、中度组（n=31）和重度组（n=20），根据治疗后临床结局分为好转组（n=68）和未好转组（n=29）。采用酶联免疫吸附法（ELISA）检测血清TRIM22 和KLF2 水平，Pearson 积矩相关分析其与改良Mayo 评分相关性，多因素Logistic 回归分析溃疡性结肠炎活动期患者未好转的影响因素，绘制ROC 曲线评估两指标对未好转的预测价值。结果 对照组、缓解期组和活动期组血清TRIM22（37.16±9.22 pg/ml，51.05±10.83 pg/ml，64.29±13.51 pg/ml）依次升高，血清KLF2（45.27±7.98 pg/ml，36.91±7.34 pg/ml，27.03±6.25 pg/ml）依次降低，差异具有统计学意义（F=121.076，143.946，均P<0.05）。轻度组、中度组和重度组血清TRIM22（56.07±11.18 pg/ml，67.29±13.04 pg/ml，78.56±13.69 pg/ml）依次升高，血清KLF2（32.07±4.95 pg/ml，25.86±4.32 pg/ml，17.25±4.09 pg/ml）依次降低，差异具有统计学意义（F=24.541，74.141，均P<0.05）。溃疡性结肠炎活动期患者血清TRIM22 与改良Mayo 评分呈正相关性（r=0.692，P<0.05），血清KLF2 与改良Mayo 评分呈负相关性（r=-0.716，P<0.05），血清TRIM22 与KLF2 呈负相关性（r=-0.659，P<0.05）。与轻度患者比较，中度和重度患者未好转风险增加（OR=1.232，2.298，均P<0.05），血清TRIM22 水平升高是未好转的危险因素（OR=1.835，P<0.05），血清KLF2 水平升高是保护因素（OR=0.731，P<0.05）。血清TRIM22，KLF2 和联合检测对未好转有预测价值，AUC 分别为0.806，0.803 和0.907，指标联合检测预测价值大于单独指标检测（Z=2.049，2.053，均P<0.05）。结论 溃疡性结肠炎活动期患者血清TRIM22 水平升高，KLF2 水平下降，并与病情严重程度及临床结局有关，指标联合检测可作为临床早期预测未好转的生化标志物。
Abstract:
Objective To explore the relationship among serum tripartite motif protein 22 (TRIM22) and Kruppel-like factor 2 (KLF2) levels, conditions and clinical outcomes of patients with active ulcerative colitis(UC). Methods A total of 97 patients with active ulcerative colitis admitted to Chongming Hospital Affiliated to Shanghai University of Medical and Health Sciences from January 2020 to January 2023 were selected as active group, 56 patients with remission (remission group) and 80 healthy volunteers (control group) as control subjects. The patients in active group were divided into mild group (n=46), moderate group (n=31) and severe group (n=20) according to severity of the disease, which also were divided into improved group (n=68) and non-improved group (n=29) according to the clinical outcome. Enzyme-linked immunosorbent assay(ELISA) was used to detect serum TRIM22 and KLF2 levels. Pearson product moment correlation analysis was used to analyze its association with modified Mayo score. Multi-factorial logistic regression analysis was used to analyze the influencing factors of failure to improve, and the ROC curve was used to assess the predictive value of serum TRIM22 and KLF2 on failure to improve. Results The levels of serum TRIM22 (37.16±9.22 pg/ml, 51.05±10.83 pg/ml, 64.29±13.51pg/ml) in control group, remission group and active group were increased in turn, while the levels of serum KLF2 (45.27±7.98 pg/ml, 36.91±7.34pg/ml, 27.03±6.25 pg/ml) in control group, remission group and active group were decreased in turn，and the differences were statistically significant (F=121.076, 143.946, all P<0.05). The levels of serum TRIM22 (56.07±11.18 pg/ml, 67.29±13.04pg/ml, 78.56±13.69 pg/ml) in mild group, moderate group and severe group were increased in turn, while the levels of serum KLF2 (32.07±4.95 pg/ml, 25.86±4.32 pg/ml, 17.25±4.09 pg/ml) in control group, remission group and active group were decreased in turn，and the differences were statistically significant (F=24.541, 74.141, all P<0.05). Serum TRIM22 was positively associated with modified Mayo score (r=0.692, P<0.05), while serum KLF2 was negatively associated with modified Mayo score (r=-0.716, P<0.05) and serum TRIM22 (r=-0.659, P<0.05) in patients with active ulcerative colitis. Compared with mild patients, moderate and severe patients with active ulcerative colitis had an increased risk of failure to improve after clinical treatment (OR=1.232, 2.298，all P<0.05). Elevated TRIM22 level was a risk factor for failure to improve after clinical treatment (OR=1.835, P<0.05) and elevated KLF2 level was a protective factor (OR=0.731, P<0.05). Serum TRIM22, KLF2 and two indicators combined had predictive value for failure to improve, with AUC of 0.806, 0.803 and 0.907, respectively. The predictive value of the combination indicators was greater than that of single indicator (Z=2.049, 2.053，all P<0.05). Conclusion Serum TRIM22 level was elevated and KLF2 was decreased in patients with active ulcerative colitis, which were related to disease severity and clinical outcome. Combined testing of two indicators can be used as the biochemical marker for early clinical prediction of failure to improve after clinical treatment.

参考文献/References:

[1] LE BERRE C, HONAP S, PEYRIN-BIROULET L. Ulcerative colitis[J]. Lancet, 2023, 402(10401):571-584.
[2] 王飞, 祝靳, 赵宝林. 溃疡性结肠炎患者血清LncRNA Mirt2 和LncRNA IFNG-AS1 表达水平及与预后相关性研究[J]. 现代检验医学杂志, 2023,38(3): 114-118, 148. WANG Fei, ZHU Jin, ZHAO Baolin. Study on the expression levels of serum LncRNA Mirt2 and LncRNA IFNGAS1 in patients with ulcerative colitis and their correlation with prognosis [J]. Journal of Modern Laboratory Medicine, 2023, 38(3): 114-118, 148.
[3] 许月仙, 李颖. 血清降钙素原和C- 反应蛋白在溃疡性结肠炎病情评估中的应用价值[J]. 中国肛肠病杂志, 2023, 43(5): 35-36. XU Yuexian, LI Ying. The application values of the serum procalcitonin and C-reactive protein in evaluating the condition of ulcerative colitis [J]. Chinese Journal of Coloproctology, 2023, 43(5): 35-36.
[4] KUCHARZIK T, KOLETZKO S, KANNENGIESSER K, et al. Ulcerative colitis-diagnostic and therapeutic algorithms[J]. Deutsches Arzteblatt International, 2020, 117(33/34): 564-574.
[5] YANG Luting, XIA Haibin. TRIM proteins in inflammation: from expression to emerging regulatory mechanisms[J]. Inflammation, 2021, 44(3): 811-820.
[6] JI Jianxiong, DING Kaikai, LUO Tao, et al. TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα[J]. Cell Death and Differentiation, 2021, 28(1): 367-381.
[7] YE Bin, LU Zhongkai. Role of TRIM22 in ulcerative colitis and its underlying mechanisms[J]. Molecular Medicine Reports, 2022, 26(2): 249.
[8] WITTNER J, SCHUH W. Krüppel-like factor 2 (KLF2) in immune cell migration[J]. Vaccines, 2021, 9(10): 1171.
[9] 陈亮, 柏洁, 郑扣龙. KLF2 在急性冠脉综合征中的作用研究[J]. 南京医科大学学报( 自然科学版),2022, 42(3): 345-351. CHEN Liang, BAI Jie, ZHENG Koulong. The role of KLF2 in acute coronary syndrome[J]. Journal of Nanjing Medical University(Natural Sciences), 2022, 42(3): 345-351.
[10] 吴开春, 梁洁, 冉志华, 等. 炎症性肠病诊断与治疗的共识意见(2018 年·北京)[J]. 中国实用内科杂志,2018, 38(9): 796-813. WU Kaichun, LIANG Jie, RAN Zhihua, et al. Chinese consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018)[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(9): 796-813.
[11] GAJENDRAN M, LOGANATHAN P, JIMENEZ G, et al. A comprehensive review and update on ulcerative colitis [J]. Disease-A-Month, 2019, 65(12): 100851.
[12] YE Lingna, CAO Qian, CHENG Jianfeng. Review of inflammatory bowel disease in China[J]. Scientific World Journal, 2013, 2013: 296470.
[13] 杨思贤, 慕奕彤, 牛福玉. 粪便S100A12, 钙卫蛋白和乳铁蛋白对溃疡性结肠炎患者疾病活动度和黏膜愈合评估价值分析[J]. 现代检验医学杂志, 2022,37(3): 172-176. YANG Sixian, MU Yitong, NIU Fuyu. Evaluation value of stool S100A12, fecal calprotectin and lactoferrin for disease activity and mucosal healing in patients with ulcerative colitis [J]. Journal of Modern Laboratory Medicine, 2022, 37(3): 172-176.
[14] GROS B, KAPLAN G G. Ulcerative colitis in adults: a review [J]. Journal of the American Medical Association, 2023, 330(10): 951-965.
[15] 卢加杰, 刘晶, 李紫琼, 等. 粪便CHI3L1 对溃疡性结肠炎镜下活动和病情严重程度的预测价值[J]. 中国现代医学杂志, 2021, 31(11): 60-64. LU Jiajie, LIU Jing, LI Ziqiong, et al. Predictive value of fecal chitinase 3-like 1 in predicting endoscopic activity and severity of ulcerative colitis[J]. China Journal of Modern Medicine, 2021, 31(11): 60-64.
[16] 曹婷婷, 张娟. 血清降钙素原和C- 反应蛋白在评价溃疡性结肠炎病情中的临床价值[J]. 数理医药学杂志, 2017, 30(8): 1153-1154. CAO Tingting, ZHANG Juan. Clinical value of serum proealcitonin and C-reactive protein in evaluating ulcerative colitis[J]. Journal of Mathematical Medicine, 2017, 30(8): 1153-1154.
[17] MERONI G. TRIM E3 ubiquitin ligases in rare genetic disorders[J]. Advances in Experimental Medicine and Biology, 2020, 1233: 311-325.
[18] DI RIENZO M, ROMAGNOLI A, ANTONIOLI M, et al. TRIM proteins in autophagy: selective sensors in cell damage and innate immune responses[J]. Cell Death and Differentiation, 2020, 27(3): 887-902.
[19] 吕洁, 齐新伟, 再海比亚·艾合买提, 等. 病毒感染时IFITM3 与TRIM22 和Foxp3 表达及关联基因的富集分析[J]. 中国病原生物学杂志, 2021, 16(1): 38-43. L? Jie, QI Xinwei, ZAIHAIBIYA·Aihemaiti, et al. Relative expression of the IFITM3 and TRIM22 genes and enrichment analysis of related genes during infection with three viruses[J]. Journal of Pathogen Biology, 2021, 16(1): 38-43.
[20] LOU Jun, WANG Yongli, ZHENG Ximing, et al. TRIM22 regulates macrophage autophagy and enhances Mycobacterium tuberculosis clearance by targeting the nuclear factor-multiplicity κB/beclin 1 pathway[J]. Journal of Cellular Biochemistry, 2018, 119(11): 8971-8980.
[21] KANG Chongyang, LU Zhaofeng, ZHU Gangyi, et al. Knockdown of TRIM22 relieves oxygen-glucose deprivation/reoxygenation-induced apoptosis and inflammation through inhibition of NF-κB/NLRP3 axis [J]. Cellular and Molecular Neurobiology, 2021, 41(2): 341-351.
[22] LIU Ronghong, ZHAO Wenzeng, WANG Haigang, et al. Long noncoding RNA LINC01207 promotes colon cancer cell proliferation and invasion by regulating miR-3125/TRIM22 axis [J]. BioMed Research International, 2020, 2020: 1216325.
[23] PAGANI I, POLI G, VICENZI E. TRIM22. A multitasking antiviral factor[J]. Cells, 2021, 10(8): 1864.
[24] DABRAVOLSKI S A, SUKHORUKOV V N, KALMYKOV V A, et al. The role of KLF2 in the regulation of atherosclerosis development and potential use of KLF2-Targeted therapy[J]. Biomedicines, 2022, 10(2): 254.
[25] THAKAR S, KATAKIA Y T, RAMAKRISHNAN S K, et al. Intermittent high glucose elevates nuclear localization of EZH2 to cause H3K27me3-dependent repression of KLF2 leading to endothelial inflammation[J]. Cells, 2021, 10(10): 2548.
[26] ZHAO Kai, TIAN Yu, WANG Junjie, et al. Fluvastatinpretreated donor cells attenuated murine aGVHD by balancing effector T cell distribution and function under the regulation of KLF2[J]. BioMed Research International, 2020, 2020: 7619849.
[27] WANG Z L, WANG Y D, WANG K, et al. KFL2 participates in the development of ulcerative colitis through inhibiting inflammation via regulating cytokines[J]. European Review for Medical And Pharmacological Sciences, 2018, 22(15): 4941-4948.
[28] TURPAEV K T. Transcription factor KLF2 and its role in the regulation of inflammatory processes[J]. Biochemistry(Mosc). 2020, 85(1): 54-67.

相似文献/References:

[1]钟 曌a,郭继勃b,郭 昊c,等.急性缺血性脑卒中患者血清Kruppel 样转录因子2 水平表达与脑梗死体积及预后的相关性研究[J].现代检验医学杂志,2023,38(06):1.[doi:10.3969/j.issn.1671-7414.2023.06.001]
　ZHONG Zhaoa,GUO Jibob,GUO Haoc,et al.Correlation between the Level of Serum Kruppel-like Transcription Factor 2 and the Volume of Cerebral Infarction and Prognosis in Patients with Acute Ischemic Stroke[J].Journal of Modern Laboratory Medicine,2023,38(04):1.[doi:10.3969/j.issn.1671-7414.2023.06.001]

备注/Memo

备注/Memo:
基金项目：上海市卫生健康委员会卫生行业临床研究专项（2020514）。
作者简介：沈丹丹（1985-），女，硕士研究生，主治医师，研究方向: 胃肠疾病诊治，E-mail：shendandan6875@126.com。
通讯作者：王鸿（1975-），女，硕士研究生，主任医师，研究方向: 胰腺疾病, E-mail：wanghong667511@163.com。
更新日期/Last Update: 2024-07-15